| Peggy L O'connor, CNP | |
|
111 North St, Rapid City, SD 57701-1163 | |
| (605) 343-0650 | |
| Not Available |
| Full Name | Peggy L O'connor |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 12 Years |
| Location | 111 North St, Rapid City, South Dakota |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1710235213 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | CP000735 (South Dakota) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cross Road Health Ministries Inc | 4688587348 | 6 |
| Cross Road Health Ministries Inc | 4688587348 | 6 |
News Archive
Emmaus Life Sciences, Inc., a biopharmaceutical company dedicated primarily to the discovery, development and commercialization of innovative treatments and therapies for rare and orphan diseases today announced that data from the Company's Phase 3 clinical trial of its pharmaceutical grade L-glutamine (PGLG) treatment for sickle cell anemia and sickle beta-0 thalassemia, will be presented, during the 9th Annual Sickle Cell Disease Research and Educational Symposium and 38th National Sickle Cell Disease Scientific Meeting.
After years of dilly dallying over it's stand on over-the-counter sales of the "morning-after" contraceptive officials at the U.S. Food and Drug Administration (FDA) suddenly appear to be doing an about turn.
Cleveland Clinic researchers have discovered the process by which high-density lipoprotein (HDL) - the so-called "good cholesterol" - becomes dysfunctional, loses its cardio-protective properties, and instead promotes inflammation and atherosclerosis, or the clogging and hardening of the arteries.
Gut diseases are difficult to diagnose in many cases, and their underlying dysfunction is hard to understand in many cases. Now, a new study published in the journal Molecular Omics promises to uncover a better insight into how these conditions occur and their mechanisms, by providing a deeper look at how genes interact in complex ways in health and fail to do so in disease.
New research has found that routine screening using a non-invasive test that analyzes fetal DNA in a pregnant woman's blood can accurately detect Down's syndrome and other genetic fetal abnormalities in the first trimester. Published early online in Ultrasound in Obstetrics & Gynecology, the results suggest that the test is superior to currently available screening strategies and could reshape standards in prenatal testing.
› Verified 4 days ago
| Entity Name | Cross Road Health Ministries Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609871391 PECOS PAC ID: 4688587348 Enrollment ID: O20040401001184 |
News Archive
Emmaus Life Sciences, Inc., a biopharmaceutical company dedicated primarily to the discovery, development and commercialization of innovative treatments and therapies for rare and orphan diseases today announced that data from the Company's Phase 3 clinical trial of its pharmaceutical grade L-glutamine (PGLG) treatment for sickle cell anemia and sickle beta-0 thalassemia, will be presented, during the 9th Annual Sickle Cell Disease Research and Educational Symposium and 38th National Sickle Cell Disease Scientific Meeting.
After years of dilly dallying over it's stand on over-the-counter sales of the "morning-after" contraceptive officials at the U.S. Food and Drug Administration (FDA) suddenly appear to be doing an about turn.
Cleveland Clinic researchers have discovered the process by which high-density lipoprotein (HDL) - the so-called "good cholesterol" - becomes dysfunctional, loses its cardio-protective properties, and instead promotes inflammation and atherosclerosis, or the clogging and hardening of the arteries.
Gut diseases are difficult to diagnose in many cases, and their underlying dysfunction is hard to understand in many cases. Now, a new study published in the journal Molecular Omics promises to uncover a better insight into how these conditions occur and their mechanisms, by providing a deeper look at how genes interact in complex ways in health and fail to do so in disease.
New research has found that routine screening using a non-invasive test that analyzes fetal DNA in a pregnant woman's blood can accurately detect Down's syndrome and other genetic fetal abnormalities in the first trimester. Published early online in Ultrasound in Obstetrics & Gynecology, the results suggest that the test is superior to currently available screening strategies and could reshape standards in prenatal testing.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Peggy L O'connor, CNP 350 Elk St., Rapid City, SD 57701 Ph: (605) 343-7262 | Peggy L O'connor, CNP 111 North St, Rapid City, SD 57701-1163 Ph: (605) 343-0650 |
News Archive
Emmaus Life Sciences, Inc., a biopharmaceutical company dedicated primarily to the discovery, development and commercialization of innovative treatments and therapies for rare and orphan diseases today announced that data from the Company's Phase 3 clinical trial of its pharmaceutical grade L-glutamine (PGLG) treatment for sickle cell anemia and sickle beta-0 thalassemia, will be presented, during the 9th Annual Sickle Cell Disease Research and Educational Symposium and 38th National Sickle Cell Disease Scientific Meeting.
After years of dilly dallying over it's stand on over-the-counter sales of the "morning-after" contraceptive officials at the U.S. Food and Drug Administration (FDA) suddenly appear to be doing an about turn.
Cleveland Clinic researchers have discovered the process by which high-density lipoprotein (HDL) - the so-called "good cholesterol" - becomes dysfunctional, loses its cardio-protective properties, and instead promotes inflammation and atherosclerosis, or the clogging and hardening of the arteries.
Gut diseases are difficult to diagnose in many cases, and their underlying dysfunction is hard to understand in many cases. Now, a new study published in the journal Molecular Omics promises to uncover a better insight into how these conditions occur and their mechanisms, by providing a deeper look at how genes interact in complex ways in health and fail to do so in disease.
New research has found that routine screening using a non-invasive test that analyzes fetal DNA in a pregnant woman's blood can accurately detect Down's syndrome and other genetic fetal abnormalities in the first trimester. Published early online in Ultrasound in Obstetrics & Gynecology, the results suggest that the test is superior to currently available screening strategies and could reshape standards in prenatal testing.
› Verified 4 days ago
Maria Sargent, CNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 353 Fairmont Blvd, Rapid City, SD 57701 Phone: 605-755-1000 | |
Kayla Sayer, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 640 Flormann St, Rapid City, SD 57701 Phone: 605-755-3300 | |
Jennifer Ann Erdman, CNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 636 Saint Anne St, Rapid City, SD 57701 Phone: 605-348-8000 Fax: 605-348-4315 | |
Natasha Gray, DNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2805 5th St, Rapid City, SD 57701 Phone: 605-755-5700 | |
Morgan Folchert, CNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1760 Centre St Ste 2, Rapid City, SD 57703 Phone: 308-249-2912 | |
Paulette A Kirby, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 811 Columbus St, Rapid City, SD 57701 Phone: 605-343-3007 | |
Rebecca Bierle, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 4150 5th St, Rapid City, SD 57701 Phone: 605-755-4300 |